MELINTA THERAPEUTICS, INC. /NEW/

MELINTA THERAPEUTICS, INC. /NEW/ insiders are currently net buyers of MLNT stock, showing bullish sentiment over the past 90 days. Executives have purchased $194.9M while selling $72.4K, resulting in a positive net flow of $194.8M. This buying activity represents 100% of total transaction volume.

MELINTA THERAPEUTICS, INC. /NEW/ has 8 active insiders who have filed SEC Form 4 transactions in the past 90 days. Holdings Llc Vatera (Executive) leads with 6 transactions totaling $194.3M. Daniel Mark Wechsler (Executive) follows with 1 transactions worth $250.0K. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. MELINTA THERAPEUTICS, INC. /NEW/'s current score of 100/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $194.9M in purchases versus $72.4K in sales.

The most recent insider transaction occurred on Jun 27, 2019, when Johnson John (Executive) disposed of 13,000 shares at $5.57 per share for $72.4K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, MLNT insider trading sentiment is currently bullish with an Alignment Score of 100/100. The net insider flow of $194.8M reflects accumulation, with 100% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like MELINTA THERAPEUTICS, INC. /NEW/. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At MLNT, we track all Form 4 filings—currently showing 14 transactions from 8 insiders over 90 days.

A 10b5-1 plan allows MELINTA THERAPEUTICS, INC. /NEW/ executives to pre-schedule stock sales when they don't possess material non-public information. At MLNT, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at MLNT appears discretionary, making insider signals more meaningful.

You can monitor MELINTA THERAPEUTICS, INC. /NEW/ (MLNT) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 8 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. MELINTA THERAPEUTICS, INC. /NEW/'s current score of 100/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $194.9M in purchases versus $72.4K in sales over 90 days, resulting in a net flow of $194.8M.

SEC Form 4 filings are mandatory reports that MELINTA THERAPEUTICS, INC. /NEW/ insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At MLNT, the most common type is "P" with 12 occurrences. The most recent Form 4 was filed on Jun 27, 2019 by Johnson John.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At MELINTA THERAPEUTICS, INC. /NEW/, approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at MLNT represents discretionary decisions with more informational value.